Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study.

Adding tirzepatide to standard care reduces one-year risk of major adverse cardiovascular events by 1.4% in patients with type 2 diabetes and established atherosclerotic disease.

• Why it matters: Understanding the real-world cardiovascular benefits of tirzepatide helps guide treatment decisions for high-risk patients, filling gaps left by clinical trials and informing clinical practice.
• What they did: The study analyzed nearly 53,000 US patients using a population-based cohort design, comparing tirzepatide initiators to sitagliptin over one year, focusing on MACE and safety outcomes.
• The result: Tirzepatide lowered the risk of MACE, myocardial infarction, infections requiring hospitalization, and all-cause mortality, supporting its potential to improve cardiovascular health beyond glucose control.